We showed that the presence of CD32B + CLS at the adipose-tumour border are associated with shorter time to metastatic disease in patients with HER2-overexpressed breast tumours who were treated with adjuvant trastuzumab. The gene discussed is FCGR2B; the disease is breast neoplasm.